Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 7/20 | 0.37 |
| ▸ | MET | P08581 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1702596 | 0.86 | CYP3A4 (0.41) | CRBNCYP3A4DYRK1BCLK1DYRK1A | |
| SCHEMBL29461413 | 0.86 | CYP3A4 (0.41) | CRBNCYP3A4DYRK1BCLK1DYRK1A | |
| SCHEMBL1703190 | 0.86 | CYP3A4 (0.41) | CRBNCYP3A4DYRK1BCLK1DYRK1A | |
| SCHEMBL1702892 | 0.85 | DYRK1B (0.46) | CRBNCYP3A4DYRK1BCLK1DYRK1A | |
| SCHEMBL1703333 | 0.84 | CYP3A4 (0.42) | CRBNCYP3A4DYRK1BCLK1DYRK1A | |
| SCHEMBL2447980 | 0.84 | CYP3A4 (0.41) | CRBNCYP3A4DYRK1BCLK1DYRK1A | |
| SCHEMBL2450698 | 0.83 | DYRK1B (0.44) | CRBNCYP3A4DYRK1BCLK1DYRK1A | |
| SCHEMBL1702882 | 0.83 | CYP3A4 (0.42) | CRBNCYP3A4DYRK1BCLK1DYRK1A | |
| SCHEMBL3727490 | 0.82 | CYP3A4 (0.41) | CRBNCYP3A4DYRK1BCLK1DYRK1A | |
| SCHEMBL1702764 | 0.82 | CYP3A4 (0.57) | CRBNCYP3A4DYRK1BCLK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440528-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-08 | — | — | EP | disclosed |
| US-8487103-B2 | Quinoline inhibitors of hepatitis C virus polymerase | ROCHE PALO ALTO LLC (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2440528-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-8026253-B2 | Quinoline inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2011-09-27 | — | — | US | disclosed |
| WO-2010142656-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, XDH, GTF3C4 | CRBN 2036/4885CYP3A4 50/4885DYRK1B 4742/4885 |
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, IRF3 | CRBN 3048/4885CYP3A4 55/4885DYRK1B 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.